| Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Co. markets Inbrija (levodopa inhalation powder), which is approved for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as needed use and utilizes Co.'s ARCUS pulmonary delivery system. Co. also markets branded Ampyra (dalfampridine), extended release tablets, 10 mg for improving walking in people with multiple sclerosis. Co.'s ARCUS development has been focused on a program for acute treatment of migraine. We show 47 historical shares outstanding datapoints in our ACOR shares outstanding history coverage, used to compute ACOR market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ACOR market cap history over the course of time is important for investors
interested in comparing ACOR's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ACOR versus a peer is one thing; comparing
ACOR market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ACOR can fluctuate over the course of history.
With this page we aim to empower investors researching ACOR by allowing them to research the ACOR market cap history.